514 related articles for article (PubMed ID: 8639263)
1. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
2. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer.
Neber DW; Roe AL
Sci Total Environ; 2001 Jul; 274(1-3):93-102. PubMed ID: 11453308
[TBL] [Abstract][Full Text] [Related]
3. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
6. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors in individual responses to environmental exposures.
Hirvonen A
J Occup Environ Med; 1995 Jan; 37(1):37-43. PubMed ID: 7620941
[TBL] [Abstract][Full Text] [Related]
8. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
9. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
Zgheib NK; Shamseddine AA; Geryess E; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; El-Saghir NS
Mutat Res; 2013; 747-748():40-7. PubMed ID: 23628324
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
15. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
16. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays.
Zhao B; Lee EJ; Wong JY; Yeoh PN; Gong NH
Pharmacogenetics; 1995 Oct; 5(5):275-80. PubMed ID: 8563767
[TBL] [Abstract][Full Text] [Related]
17. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly AK; Cholerton S; Armstrong M; Idle JR
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
[TBL] [Abstract][Full Text] [Related]
18. [Genetic and phenotypic polymorphisms in carcinogen-metabolizing enzymes and cancer susceptibility].
Watanabe M
Nihon Rinsho; 1996 Aug; 54(8):2261-75. PubMed ID: 8810806
[TBL] [Abstract][Full Text] [Related]
19. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
Nebert DW
Clin Chem Lab Med; 2000 Sep; 38(9):857-61. PubMed ID: 11097340
[TBL] [Abstract][Full Text] [Related]
20. Metabolic polymorphisms and cancer susceptibility.
Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]